iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE) Reaches New 52-Week High at $69.57

iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE) reached a new 52-week high during trading on Tuesday . The company traded as high as $69.57 and last traded at $69.50, with a volume of 9268 shares trading hands. The stock had previously closed at $68.50.

iShares U.S. Pharmaceuticals ETF Stock Performance

The company’s fifty day simple moving average is $67.36 and its two-hundred day simple moving average is $66.56. The company has a market capitalization of $701.75 million, a price-to-earnings ratio of 6.49 and a beta of 0.58.

Institutional Investors Weigh In On iShares U.S. Pharmaceuticals ETF

A number of institutional investors have recently made changes to their positions in IHE. Fisher Asset Management LLC increased its stake in iShares U.S. Pharmaceuticals ETF by 5,567.8% during the fourth quarter. Fisher Asset Management LLC now owns 1,208,199 shares of the company’s stock valued at $224,003,000 after purchasing an additional 1,186,882 shares during the last quarter. McElhenny Sheffield Capital Management LLC bought a new stake in shares of iShares U.S. Pharmaceuticals ETF during the 2nd quarter valued at about $18,942,000. Aptus Capital Advisors LLC acquired a new stake in iShares U.S. Pharmaceuticals ETF during the second quarter worth about $12,165,000. Accurate Wealth Management LLC bought a new position in iShares U.S. Pharmaceuticals ETF in the first quarter worth about $7,364,000. Finally, Concord Investment Counsel Inc. acquired a new position in iShares U.S. Pharmaceuticals ETF in the first quarter valued at approximately $3,880,000.

iShares U.S. Pharmaceuticals ETF Company Profile

iShares U.S. Pharmaceuticals ETF, formerly iShares Dow Jones U.S. Pharmaceuticals Index Fund (the Fund), is an exchange traded fund. The Fund seeks investment results that correspond generally to the price and yield performance of the Dow Jones U.S. Select Pharmaceuticals Index (the Index). The Index measures the performance of the pharmaceuticals sector of the United States equity market, and includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines, but excludes producers of vitamins.